Skip to main content
All lobbying filings

ARENTFOX SCHIFF LLP

Lobbying for ORGANOGENESIS INC. · Biotech company

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 18, 2026
Income
$80,000.00
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 3
  • Centers For Medicare and Medicaid Services (CMS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 3
  • HR 5768
    Skin Substitute Access and Payment Reform Act
  • S 2561
    Skin Substitute Access and Payment Reform Act of 2025
  • HR 6852
    Advanced Wound Care and Regenerative Medicine Access and Reform Act
 Lobbying activity 2
Medicare/Medicaid

Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations and Discarded Products policy Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products (CY2026 and CY2027) Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026 and CY2027) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R.6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill

Health Issues

Food and Drug Administration policy on chronic wound healing products

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem